LAUSR

1. Long CL, Raebel MA, Price DW, et al. Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother. 2004;38:853–858. 2. Brück K, Stel VS, Gambaro G, et al. CKD prevalence varies across the European general population. J Am Soc Nephrol. 2016;27:2135–2147. 3. Helld en A, Odar-Cederlöf I, Diener P, et al. High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study. Nephrol Dial Transpl. 2003;18:1135–1141. 4. Vander T, Medvedovsky M, Herishanu Y. Encephalopathy induced by oral acyclovir in a patient with normal renal function. J Infect. 2003;46:286. 5. Gentry JL, Peterson C. Death delusions and myoclonus: acyclovir toxicity. Am J Med. 2015;128:692–694. 6. Asahi T, Tsutsui M, Wakasugi M, et al. Valacyclovir neurotoxicity: clinical experience and review of the literature. Eur J Neurol. 2009;16:457–460. 7. Beales P, Almond MK, Kwan JTC. Acyclovir neurotoxicity following oral therapy: prevention and treatment in patients on haemodialysis. Nephron. 1994;66:362–363. 8. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245. 9. Chowdhury MA, Derar N, Hasan S, et al. Acyclovirinduced neurotoxicity: a case report and review of literature. Am J Ther. 2016;23:e941–3. 10. de Knegt RJ, van der Pijl H, van Es LA. Acyclovirassociated encephalopathy, lack of relationship between acyclovir levels and symptoms. Nephrol Dial Transplant. 1995;10:1775–1777.